RxDoctor Payments Data

Christopher Papp, MD

Ophthalmology · South Lyon, MINPI 1669493342

Payments from drug & device makers

$1,119in general payments, 2019–2025

Across 48 payments — averaging $23.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$175
  • Novartis$119
  • Rxsight Inc$111
  • Bausch & Lomb Americas Inc.$100
  • Genentech USA, Inc.$92
  • Tarsus Pharmaceuticals, Inc.$79
  • plus $445 from 13 others

What the payments were for

  • Food & beverage$1,02191%
  • Education$474%
  • Entertainment$525%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,119 in reported general payments places this provider in the 45th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$366,574
Medicare patients
657
Services billed
3,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine32$21,457
Prednisolone Acetate307$18,633
Restasis MultidoseCyclosporine20$12,436
LumiganBimatoprost20$9,140
RocklatanNetarsudil Mesylat/Latanoprost19$6,702
TobradexTobramycin/Dexamethasone19$4,882
Latanoprost328$4,359
Cyclosporine11$4,109
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat61$1,568
Timolol Maleate32$1,350
Ketorolac Tromethamine20$551
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha18$229
Brimonidine Tartrate17$194
ErythromycinErythromycin Base11$126
Dorzolamide Hcl14$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose, Lumigan$15$43,03272 claims
Aerie Pharmaceuticals, Inc.Rocklatan$63$6,70219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in South Lyon

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →